Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1767-1774

  Trunzer, Kerstin ^a   Pavlick, Anna C ^b   Schuchter, Lynn ^c   Gonzalez, Rene ^e   McArthur, Grant A ^f   Hutson, Thomas E ⁱ   Moschos, Stergios J ^d   Flaherty, Keith T ^k   Kim, Kevin B ^j   Weber, Jeffrey S ^l   Hersey, Peter ^g   Long, Georgina V ^h   Lawrence, Donald ^k   Ott, Patrick A ^b   Amaravadi, Ravi K ^c   Lewis, Karl D ^e   Puzanov, Igor ^m   Lo, Roger S ⁿ   Koehler, Astrid ^q   Kockx, Mark ^r   Spleiss, Olivia ^a   Schell Steven, Annette ^a   Gilbert, Houston N ^o   Cockey, Louise ^a   Bollag, Gideon ^p   Lee, Richard J ^s   Joe, Andrew K ^s   Sosman, Jeffrey A ^m   Ribas, Antoni ⁿ   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m VANDERBILT INGRAM CANCER CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o GENENTECH INC   (United States)

^p PLEXXIKON INC   (United States)

^q ROCHE DIAGNOSTICS GMBH   (Germany)

^r Histogenex   (Belgium)

^s HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYCLIN D1; DNA; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PHOSPHORYLATED AKT PROTEIN; PHOSPHORYLATED EXTRACELLULAR SIGNAL RELATED KINASE; PHOSPHORYLATED MEK PROTEIN; PROTEIN P27; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; INDOLE DERIVATIVE; MAP2K1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NRAS PROTEIN, HUMAN; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRINSIC ACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; ONCOGENE N RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; POINT MUTATION; SKIN TUMOR; TUMOR CELL CULTURE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84879496934     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.7888     Document Type: Article

References (30)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
2. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by onco-genic mutations of B-RAF. Cell 116:855-867, 2004
3. Dhomen N, Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17:31-39, 2007
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
5. Bollag G, Hirth P, Tsai J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599, 2010
6. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
7. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
8. Paraiso KH, Fedorenko IV, Cantini LP, et al: Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102:1724-1730, 2010
9. McArthur G, Ribas A, Chapman PB, et al: Molecular analyses from a phase I trial of vemu-rafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation positive metastatic melanoma patients (pts). J Clin Oncol 29, 2011 (suppl; abstr 8502)
10. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012
11. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimeriza-tion of aberrantly spliced BRAF (V600E). Nature 480:387-390, 2011
12. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
13. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106: 20411-20416, 2009
14. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011
15. Johannessen CM, Boehm JS, Kim SY, et al COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972, 2010
16. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 683-695, 2010
17. Shi H, Kong X, Ribas A, et al: Combinatorial treatments that overcome PDGFR/3-driven resistance of melanoma cells to V600EB-RAF inhibition Cancer Res 71:5067-5074, 2011
18. Atefi M, von Euw E, Attar N, et al: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6:e28973, 2011
19. Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-6681, 2010
20. Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-2883, 2008
21. Xing F, Persaud Y, Pratilas CA, et al: Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31:446-457, 2012
22. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-2760, 2011
23. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992
24. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22:3113-3122, 2003
25. Søndergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010
26. Nathanson KL, Martin A, Letrero R, et al Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29, 2011 (suppl; abstr 8501)
27. Lucero OM, Dawson DW, Moon RT, et al: A Re-evaluation of the "oncogenic" nature of Wnt//3-catenin signaling in melanoma and other cancers Curr Oncol Rep 12:314-318, 2010
28. Chien AJ, Moore EC, Lonsdorf AS, et al Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106:1193-1198, 2009
29. Shi H, Moriceau G, Kong X, et al: Sensitivity of B-RAF/MEK1 double-mutant melanomas to B-RAF nhibitors. Cancer Discov 2:414-424, 2012
30. Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-139, 2011